All News

2020

May

Media Release / May 13, 2020

Sandoz Glatopa® demonstrates trend towards lower relapse rates and costs for MS patients in US compared to originator medicine in real-world study

Read More

April

Media Release / Apr 02, 2020

Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo

Read More

March

Media Release / Mar 30, 2020

Novartis donates 20,000 doses of hydroxychloroquine for COVID-19 PEP clinical trial

Read More
Media Release / Mar 29, 2020

Novartis donation: Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services

Read More
Media Release / Mar 23, 2020

Sandoz acquires US distribution rights to two key hospital injectable medicines, reinforcing strategic focus on key growth segment

Read More
Media Release / Mar 20, 2020

Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response

Read More
Media Release / Mar 02, 2020

Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.

Read More

February

Media Release / Feb 06, 2020

AAM names Carol Lynch, Vice Chair of the Board

Read More
2019

November

Media Release / Nov 05, 2019

Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez)

Read More
Media Release / Nov 04, 2019

Sandoz lowers Glatopa® (glatiramer acetate injection) price in US to offer people with MS high-quality care at a more affordable price

Read More